Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03517449 · FLOW

Participant flow

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) · Source last updated 2026-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.
    id
    FG000
    title
    Lenvatinib 20 mg + Pembrolizumab 200 mg
  2. description
    Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
    id
    FG001
    title
    Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        411
      2. group Id
        FG001
        num Subjects
        416
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        411
      2. group Id
        FG001
        num Subjects
        416
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 1178 participants were screened, of which 351 were screen failures and 827 (697 mismatch repair proficient \[pMMR\] participants and 130 MMR deficient \[dMMR\] participants) were enrolled and randomized, out of which 794 participants were treated.
recruitment Details
Participants took part in the study at 167 investigative sites in Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, Poland, Russia, Spain, Taiwan, Turkey, United Kingdom and the United States
Complete source fields
groups
  1. description
    Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.
    id
    FG000
    title
    Lenvatinib 20 mg + Pembrolizumab 200 mg
  2. description
    Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
    id
    FG001
    title
    Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        411
      2. group Id
        FG001
        num Subjects
        416
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        411
      2. group Id
        FG001
        num Subjects
        416
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 1178 participants were screened, of which 351 were screen failures and 827 (697 mismatch repair proficient \[pMMR\] participants and 130 MMR deficient \[dMMR\] participants) were enrolled and randomized, out of which 794 participants were treated.
recruitment Details
Participants took part in the study at 167 investigative sites in Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, Poland, Russia, Spain, Taiwan, Turkey, United Kingdom and the United States

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice